Carlos AlmeidaRamosMD

Clinical Trials

• CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL Start of enrollment: 2009 Feb 01

  Active, not recruiting

  Phase 1

• T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL Start of enrollment: 2009 Jul 01

  Active, not recruiting

  Phase 1

• Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL Start of enrollment: 2009 Jul 01

  Recruiting

  Phase 1

• Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases Start of enrollment: 2012 Feb 01

  Completed

  Phase 1

• CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) Start of enrollment: 2020 Jun 22

  Recruiting

  Phase 1

  Roles: Principal Investigator, Contact

• Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas Start of enrollment: 2020 Sep 16

  Recruiting

  Phase 1

• Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) Start of enrollment: 2014 Apr 01

  Active, not recruiting

  Phase 1

  Roles: Principal Investigator, Contact

• Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy Start of enrollment: 2022 Jul 25

  Active, not recruiting

  Phase 1

  Roles: Contact

• CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) Start of enrollment: 2017 May 08

  Recruiting

  Phase 1

  Roles: Principal Investigator, Contact

• Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) Start of enrollment: 2014 Feb 01

  Recruiting

  Phase 1

  Roles: Principal Investigator, Contact

• Join now to see all